Oruka Therapeutics (ORKA) Total Current Liabilities (2010 - 2026)

Oruka Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $16.6 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 41.88% year-over-year to $16.6 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 41.88% increase from a year earlier, with the FY2025 full-year figure at $15.4 million, up 17.87% from the prior year.
• Total Current Liabilities grew to $16.6 million in Q1 2026 per ORKA's latest filing, from $15.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $21.0 million in Q3 2025 and bottomed at $637000.0 in Q4 2023.
• The 5-year median for Total Current Liabilities is $2.7 million (2022), against an average of $7.3 million.
• Across the five-year window, Total Current Liabilities plunged 67.64% in 2022 and surged 1947.57% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $1.1 million in 2022, then tumbled by 43.73% to $637000.0 in 2023, then jumped by 1947.57% to $13.0 million in 2024, then increased by 17.87% to $15.4 million in 2025, then grew by 8.19% to $16.6 million in 2026.
• Per Business Quant, the three latest ORKA Total Current Liabilities figures stand at $16.6 million (Q1 2026), $15.4 million (Q4 2025), and $21.0 million (Q3 2025).